A virus most people don't take seriously enough
RSV — respiratory syncytial virus — sounds like something that only affects babies. And yes, it's well-known as a serious illness in infants. But RSV sends hundreds of thousands of older adults to the hospital every year.
For someone with COPD (a lung disease that makes breathing difficult), asthma, diabetes, or obesity, an RSV infection is not just a bad cold. It can trigger a dangerous flare-up, pneumonia, or even a cardiovascular event (a problem with the heart triggered by severe infection and inflammation).
Why this moment matters
Several RSV vaccines have recently become available for older adults — a major shift from just a few years ago when no such options existed. But a key question remained: do these vaccines work as well for people who have other health conditions? Those are often the very people who need protection most.
The old situation vs. what this study adds
Previous data confirmed that the AS01E-adjuvanted RSVPreF3 vaccine (sold under the brand name Arexvy) worked well in the general population of adults 60 and older. What wasn't fully clear was whether that protection held up specifically for people with COPD, asthma, diabetes, or obesity — and for how long.
But here's what makes this data stand out: a single pre-season shot appeared to maintain meaningful protection across not one, not two, but three consecutive RSV seasons.
This vaccine contains a piece of the RSV virus called the prefusion F protein — essentially a snapshot of the virus in the shape it takes just before it tries to invade a cell. Your immune system sees this protein, builds defenses against it, and remembers it.
Think of it like giving your immune system a wanted poster of the virus before it shows up. When real RSV arrives, the immune system recognizes it immediately and acts fast. The AS01E adjuvant (an ingredient that boosts the immune response) makes that wanted poster stick in the immune system's memory longer.
Who was studied
This analysis drew from a large international Phase 3 clinical trial called AReSVi-006, which ran from May 2021 to May 2024. More than 24,000 adults aged 60 and older were enrolled. They were randomly assigned to receive either one dose of the vaccine or a placebo (an inactive injection) before RSV season. Researchers then looked specifically at subgroups of participants who had COPD, asthma, diabetes, or obesity.
The vaccine cut the risk of lower respiratory tract disease caused by RSV by about 75 percent in people with COPD, 66 percent in those with asthma, 70 percent in diabetic participants, and 74 percent in those with obesity. Those numbers are comparable to — and in some cases better than — the protection seen in the overall study population.
In people with COPD, the vaccine also reduced dangerous complications: vaccinated participants were significantly less likely to need systemic corticosteroids (strong anti-inflammatory medications) or antibiotics to manage their RSV illness.
These reductions in steroid and antibiotic use matter because both of those treatments carry their own risks and side effects when used repeatedly.
That's not the whole story
These subgroup findings are exploratory. The trial was not originally designed to specifically test each subgroup separately, which means the results should be interpreted with some caution. Smaller subgroups produce less statistically reliable estimates, and some of the confidence intervals — the range of uncertainty around each number — are wide.
The bigger picture
This data adds to a growing body of evidence that RSV vaccination in older adults is not just for the healthiest seniors. For people who are most vulnerable to severe RSV illness — those managing chronic lung disease, metabolic conditions, or excess weight — the vaccine may offer some of the most meaningful protection.
If you are 60 or older and have COPD, asthma, diabetes, or obesity, this is a conversation worth having with your doctor before the next RSV season. Several RSV vaccines are now available and recommended by health authorities in many countries. The RSVPreF3 vaccine is among them. Your doctor can help you weigh the benefits against any personal factors.
Limitations to keep in mind
This was a post-hoc analysis — meaning the subgroup comparisons were planned and run after the main trial data was already collected. That approach can reveal useful patterns, but it also increases the chance of finding results by chance. Larger studies designed specifically around high-risk subgroups would strengthen these findings.
Where this research is headed
Researchers are continuing to monitor long-term protection from a single dose and are investigating whether booster doses might extend immunity further. The question of whether annual revaccination offers additional benefit in high-risk groups is also being explored.